Status
Conditions
Treatments
About
This prospective study enrolls subjects who have clinical and laboratory manifestations related with hemophagocytic lymphohistiocytosis. The purpose of the study is to evaluate clinical and biological features of adult hemophagocytic lymphohistiocytosis. The enrolled subjects into this study will be evaluated according to the HLH (hemophagocytic lymphohistiocytosis)criteria and treated with systemic immunosuppressive therapy or chemotherapy. All subjects will be regularly monitored by physicians participating in this study.
Full description
Study process is as follows.
Informed consent for subjects fulfilling the inclusion criteria.
Laboratory evaluation will be done for subjects according to the following diagnostic criteria.
Diagnosis will be established if one of either 1 or 2 below is fulfilled
fever ≥ 38.5'C for ≥ 7 days
splenomegaly ≥ 3 finger breadth below left subcostal margin
cytopenias affecting ≥2 of 3 lineages in peripheral blood (Hemoglobin < 9 g/L, Platelets < 100 × 109/L, Absolute neutrophil count < 1.0 × 109/L)
Hypertriglyceridemia and/or hypofibrinogenemia: Fasting triglycerides ≥ 265 mg/dL, fibrinogen ≤ 1.5 g/L
Hemophagocytosis in bone marrow or spleen or lymph node
Low or absent NK-cell activity (according to local laboratory reference)
Ferritin ≥ 500 mcg/L
Soluble CD25 (sIL-2 receptor) ≥ 2,400 U/mL
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
Subjects should fulfill the following criteria
Subjects should have at least one of the following problems
Age > 18 years
Written informed consents
Exclusion Criteria:
Subjects cannot satisfy the inclusion criteria
81 participants in 1 patient group
Loading...
Central trial contact
Seok Jin Kim, MD, PhD; Silvia Park, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal